New drug cocktail shows promise for Tough-to-Treat uterine cancer
NCT ID NCT03694262
First seen Mar 25, 2026 · Last updated May 23, 2026 · Updated 11 times
Summary
This study tested a combination of three drugs (bevacizumab, atezolizumab, and rucaparib) in 30 people with recurrent or progressive endometrial cancer that had not responded to prior treatments. The goal was to see if the combination could shrink tumors or slow cancer growth. Participants received the drugs intravenously and orally over cycles, and researchers measured how many responded to treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Froedtert Lutheran Memorial Hospital
Milwaukee, Wisconsin, 53226, United States
-
Mount Sinai
New York, New York, 10029, United States
-
St. Luke's Hospital and Health Network
Bethlehem, Pennsylvania, 18015, United States
Conditions
Explore the condition pages connected to this study.